Integrated physiology and systems biology of PPARα

Molecular Metabolism

Volumn 3, Issue 4, 2014, Pages 354-371

  Kersten, Sander ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Expression profiling; Lipid metabolism; Liver; Metabolic homeostasis; PPAR ; Systems biology; Transcriptional networks

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 4; FATTY ACID; FATTY ACID DERIVATIVE; FIBROBLAST GROWTH FACTOR 1; HYDROLASE; MANNOSE BINDING LECTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; RETINOID; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID; VANIN 1;

ADAPTIVE IMMUNITY; AMINO ACID METABOLISM; BINDING AFFINITY; CARCINOGENICITY; CISTROME; DIET SUPPLEMENTATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GENE EXPRESSION REGULATION; GENE STRUCTURE; GENE TARGETING; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; HUMAN; HYDROLYSIS; KETOGENESIS; KETOGENIC DIET; LIPID DIET; LIPID HOMEOSTASIS; LIPID STORAGE; LIPOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; SYSTEMS BIOLOGY; VITAMIN METABOLISM;

EID: 84902355023     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.02.002     Document Type: Review

References (255)

1. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650.
2. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68:879-887.
3. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
4. Gronemeyer H., Laudet V. Transcription factors 3: nuclear receptors. Protein Profile 1995, 2:1173-1308.
5. Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO Journal 1992, 11:433-439.
6. Lefterova M.I., Zhang Y., Steger D.J., Schupp M., Schug J., Cristancho A., et al. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes & Development 2008, 22:2941-2952.
7. DiRenzo J., Soderstrom M., Kurokawa R., Ogliastro M.H., Ricote M., Ingrey S., et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Molecular and Cellular Biology 1997, 17:2166-2176.
8. Mukherjee R., Davies P.J., Crombie D.L., Bischoff E.D., Cesario R.M., Jow L., et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997, 386:407-410.
9. Schulman I.G., Shao G., Heyman R.A. Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function. Molecular and Cellular Biology 1998, 18:3483-3494.
10. Yu S., Reddy J.K. Transcription coactivators for peroxisome proliferator-activated receptors. Biochimica et Biophysica Acta 2007, 1771:936-951.
11. Viswakarma N., Jia Y., Bai L., Vluggens A., Borensztajn J., Xu J., et al. Coactivators in PPAR-regulated gene expression. PPAR Research 2010, 2010. pii: 250126. http://dx.doi.org/10.1155/2010/250126.
12. Venteclef N., Jakobsson T., Steffensen K.R., Treuter E. Metabolic nuclear receptor signaling and the inflammatory acute phase response. Trends in Endocrinology and Metabolism: TEM 2011, 22:333-343.
13. Georgiadi A., Kersten S. Mechanisms of gene regulation by fatty acids. Advances in Nutrition 2012, 3:127-134.
14. Bookout A.L., Jeong Y., Downes M., Yu R.T., Evans R.M., Mangelsdorf D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006, 126:789-799.
15. Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001, 142:4195-4202.
16. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature 2000, 405:421-424.
17. Georgiadi A., Boekschoten M.V., Muller M., Kersten S. Detailed transcriptomics analysis of the effect of dietary fatty acids on gene expression in the heart. Physiological Genomics 2012, 44:352-361.
18. Madrazo J.A., Kelly D.P. The PPAR trio: regulators of myocardial energy metabolism in health and disease. Journal of Molecular and Cellular Cardiology 2008, 44:968-975.
19. Bunger M., van den Bosch H.M., van der Meijde J., Kersten S., Hooiveld G.J., Muller M. Genome-wide analysis of PPARalpha activation in murine small intestine. Physiological Genomics 2007, 30:192-204.
20. Cahill G.F. Fuel metabolism in starvation. Annual Review of Nutrition 2006, 26:1-22.
21. Hashimoto T., Cook W.S., Qi C., Yeldandi A.V., Reddy J.K., Rao M.S. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. Journal of Biological Chemistry 2000, 275:28918-28928.
22. Kersten S., Seydoux J., Peters J.M., Gonzalez F.J., Desvergne B., Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. Journal of Clinical Investigation 1999, 103:1489-1498.
23. Leone T.C., Weinheimer C.J., Kelly D.P. Acritical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:7473-7478.
24. Patsouris D., Mandard S., Voshol P.J., Escher P., Tan N.S., Havekes L.M., et al. PPARalpha governs glycerol metabolism. Journal of Clinical Investigation 2004, 114:94-103.
25. Sugden M.C., Bulmer K., Gibbons G.F., Knight B.L., Holness M.J. Peroxisome-proliferator-activated receptor-alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. Biochemical Journal 2002, 364:361-368.
26. Sanderson L.M., Boekschoten M.V., Desvergne B., Muller M., Kersten S. Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiological Genomics 2010, 41:42-52.
27. Makowski L., Noland R.C., Koves T.R., Xing W., Ilkayeva O.R., Muehlbauer M.J., et al. Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB Journal 2009, 23:586-604.
28. Le May C., Pineau T., Bigot K., Kohl C., Girard J., Pegorier J.P. Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression. FEBS Letters 2000, 475:163-166.
29. Atherton H.J., Gulston M.K., Bailey N.J., Cheng K.K., Zhang W., Clarke K., et al. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse. Molecular Systems Biology 2009, 5:259.
30. De Souza A.T., Dai X., Spencer A.G., Reppen T., Menzie A., Roesch P.L., et al. Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids Research 2006, 34:4486-4494.
31. Xu J., Xiao G., Trujillo C., Chang V., Blanco L., Joseph S.B., et al. Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. Journal of Biological Chemistry 2002, 277:50237-50244.
32. Bandsma R.H., Van Dijk T.H., Harmsel At A., Kok T., Reijngoud D.J., Staels B., et al. Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor alpha-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast. Journal of Biological Chemistry 2004, 279:8930-8937.
33. Mandard S., Stienstra R., Escher P., Tan N.S., Kim I., Gonzalez F.J., et al. Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors. Cellular and Molecular Life Sciences 2007, 64:1145-1157.
34. Derks T.G., van Dijk T.H., Grefhorst A., Rake J.P., Smit G.P., Kuipers F., et al. Inhibition of mitochondrial fatty acid oxidation invivo only slightly suppresses gluconeogenesis but enhances clearance of glucose in mice. Hepatology 2008, 47:1032-1042.
35. Rakhshandehroo M., Sanderson L.M., Matilainen M., Stienstra R., Carlberg C., de Groot P.J., et al. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Research 2007, 2007:26839.
36. Xu J., Chang V., Joseph S.B., Trujillo C., Bassilian S., Saad M.F., et al. Peroxisomal proliferator-activated receptor alpha deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux. Endocrinology 2004, 145:1087-1095.
37. Knauf C., Rieusset J., Foretz M., Cani P.D., Uldry M., Hosokawa M., et al. Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: role in liver and brain. Endocrinology 2006, 147:4067-4078.
38. Kersten S., Mandard S., Escher P., Gonzalez F.J., Tafuri S., Desvergne B., et al. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB Journal 2001, 15:1971-1978.
39. Ciana P., Biserni A., Tatangelo L., Tiveron C., Sciarroni A.F., Ottobrini L., et al. Anovel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver. Molecular Endocrinology 2007, 21:388-400.
40. Gottlicher M., Widmark E., Li Q., Gustafsson J.A. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:4653-4657.
41. Chakravarthy M.V., Pan Z., Zhu Y., Tordjman K., Schneider J.G., Coleman T., et al. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metabolism 2005, 1:309-322.
42. Sanderson L.M., Degenhardt T., Koppen A., Kalkhoven E., Desvergne B., Muller M., et al. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Molecular and Cellular Biology 2009, 29:6257-6267.
43. Lemberger T., Saladin R., Vazquez M., Assimacopoulos F., Staels B., Desvergne B., et al. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. Journal of Biological Chemistry 1996, 271:1764-1769.
44. Gachon F., Leuenberger N., Claudel T., Gos P., Jouffe C., Fleury Olela F., et al. Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor alpha (PPARalpha) activity. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:4794-4799.
45. Haemmerle G., Moustafa T., Woelkart G., Buttner S., Schmidt A., van de Weijer T., et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nature Medicine 2011, 17:1076-1085.
46. Ong K.T., Mashek M.T., Bu S.Y., Greenberg A.S., Mashek D.G. Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology 2011, 53:116-126.
47. Settembre C., De Cegli R., Mansueto G., Saha P.K., Vetrini F., Visvikis O., et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nature Cell Biology 2013, 15:647-658.
48. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:4312-4317.
49. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Molecular and Cellular Biology 1995, 15:3012-3022.
50. Duval C., Muller M., Kersten S. PPARalpha and dyslipidemia. Biochimica et Biophysica Acta 2007, 1771:961-971.
51. Staels B., Maes M., Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nature clinical practice. Cardiovascular Medicine 2008, 5:542-553.
52. Peters J.M., Cattley R.C., Gonzalez F.J. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997, 18:2029-2033.
53. Gonzalez F.J. The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis. Molecular and Cellular Endocrinology 2002, 193:71-79.
54. Mukherjee R., Strasser J., Jow L., Hoener P., Paterniti J.R., Heyman R.A. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels invivo. Arteriosclerosis Thrombosis and Vascular Biology 1998, 18:272-276.
55. Wang Y., Yao R., Maciag A., Grubbs C.J., Lubet R.A., You M. Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide. Molecular Cancer Therapeutics 2006, 5:1060-1072.
56. Martin P.G., Lasserre F., Calleja C., Van Es A., Roulet A., Concordet D., et al. Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks. Gene Expression 2005, 12:177-192.
57. Ouamrane L., Larrieu G., Gauthier B., Pineau T. RXR activators molecular signalling: involvement of a PPAR alpha-dependent pathway in the liver and kidney, evidence for an alternative pathway in the heart. British Journal of Pharmacology 2003, 138:845-854.
58. Cornu-Chagnon M.C., Dupont H., Edgar A. Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundamental and Applied Toxicology: Official Journal of the Society of Toxicology 1995, 26:63-74.
59. Gray T.J., Lake B.G., Beamand J.A., Foster J.R., Gangolli S.D. Peroxisome proliferation in primary cultures of rat hepatocytes. Toxicology and Applied Pharmacology 1983, 67:15-25.
60. Lake B.G., Gray T.J., Pels Rijcken W.R., Beamand J.A., Gangolli S.D. The effect of hypolipidaemic agents on peroxisomal beta-oxidation and mixed-function oxidase activities in primary cultures of rat hepatocytes. Relationship between induction of palmitoyl-CoA oxidation and lauric acid hydroxylation. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 1984, 14:269-276.
61. Paul H.S., Adibi S.A. Paradoxical effects of clofibrate on liver and muscle metabolism in rats. Induction of myotonia and alteration of fatty acid and glucose oxidation. Journal of Clinical Investigation 1979, 64:405-412.
62. Furuta S., Miyazawa S., Hashimoto T. Induction of acyl-CoA dehydrogenases and electron transfer flavoprotein and their roles in fatty acid oxidation in rat liver mitochondria. Journal of Biochemistry 1981, 90:1751-1756.
63. Glatz J.F., Wagenmakers A.J., Veerkamp J.H., van Moerkerk H.T. Effect of clofibrate feeding on palmitate and branched-chain 2-oxo acid oxidation in rat liver and muscle. Biochemical Pharmacology 1983, 32:2489-2493.
64. Kahonen M.T., Ylikahri R.H. Effect of clofibrate and gemfibrozil on the activities of mitochondrial carnitine acyltransferases in rat liver. Dose-response relations. Atherosclerosis 1979, 32:47-56.
65. Kawashima Y., Katoh H., Watanuki H., Takegishi M., Kozuka H. Effects of long-term administration of clofibric acid on peroxisomal beta-oxidation, fatty acid-binding protein and cytosolic long-chain acyl-CoA hydrolases in rat liver. Biochemical Pharmacology 1985, 34:325-329.
66. Mannaerts G.P., Debeer L.J., Thomas J., De Schepper P.J. Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats. Journal of Biological Chemistry 1979, 254:4585-4595.
67. Mortensen P.B., Rasmussen K. Beta-oxidation of C-6-C-10 fatty acids in rat liver homogenates measured by selected ion monitoring: effects of cyanide and clofibrate. Biomedical Mass Spectrometry 1983, 10:528-533.
68. Pande S.V., Parvin R. Clofibrate enhancement of mitochondrial carnitine transport system of rat liver and augmentation of liver carnitine and gamma-butyrobetaine hydroxylase activity by thyroxine. Biochimica et Biophysica Acta 1980, 617:363-370.
69. Reddy M.K., Lalwani N.D., Qureshi S.A., Reddy J.K. Induction of hamster hepatic peroxisomal beta-oxidation and peroxisome proliferation-associated 80000mol.wt. polypeptide by hypolipidemic drugs. Human Toxicology 1982, 1:135-147.
70. Bodnar A.G., Rachubinski R.A. Cloning and sequence determination of cDNA encoding a second rat liver peroxisomal 3-ketoacyl-CoA thiolase. Gene 1990, 91:193-199.
71. Ozasa H., Miyazawa S., Furuta S., Osumi T., Hashimoto T. Induction of peroxisomal beta-oxidation enzymes in primary cultured rat hepatocytes by clofibric acid. Journal of Biochemistry 1985, 97:1273-1278.
72. Reddy J.K., Goel S.K., Nemali M.R., Carrino J.J., Laffler T.G., Reddy M.K., et al. Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:1747-1751.
73. Kahonen M. Effect of clofibrate treatment on acylcarnitine oxidation in isolated rat liver mitochondria. Medical Biology 1979, 57:58-65.
74. Lazarow P.B., De Duve C. Afatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. Proceedings of the National Academy of Sciences of the United States of America 1976, 73:2043-2046.
75. Osmundsen H., Cervenka J., Bremer J. Arole for 2,4-enoyl-CoA reductase in mitochondrial beta-oxidation of polyunsaturated fatty acids. Effects of treatment with clofibrate on oxidation of polyunsaturated acylcarnitines by isolated rat liver mitochondria. Biochemical Journal 1982, 208:749-757.
76. Veitch K., Draye J.P., Van Hoof F., Sherratt H.S. Effects of riboflavin deficiency and clofibrate treatment on the five acyl-CoA dehydrogenases in rat liver mitochondria. Biochemical Journal 1988, 254:477-481.
77. Orton T.C., Parker G.L. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid. Drug Metabolism and Disposition: the Biological Fate of Chemicals 1982, 10:110-115.
78. Sharma R., Lake B.G., Gibson G.G. Co-induction of microsomal cytochrome P-452 and the peroxisomal fatty acid beta-oxidation pathway in the rat by clofibrate and di-(2-ethylhexyl)phthalate. Dose-response studies. Biochemical Pharmacology 1988, 37:1203-1206.
79. Sharma R.K., Lake B.G., Makowski R., Bradshaw T., Earnshaw D., Dale J.W., et al. Differential induction of peroxisomal and microsomal fatty-acid-oxidising enzymes by peroxisome proliferators in rat liver and kidney. Characterisation of a renal cytochrome P-450 and implications for peroxisome proliferation. European Journal of Biochemistry 1989, 184:69-78.
80. Bergseth S., Christiansen E.N., Bremer J. The effect of feeding fish oils, vegetable oils and clofibrate on the ketogenesis from long chain fatty acids in hepatocytes. Lipids 1986, 21:508-514.
81. el Kebbaj M.H., Cherkaoui Malki M., Latruffe N. Effect of peroxisomes proliferators and hypolipemic agents on mitochondrial inner membrane linked D-3-hydroxybutyrate dehydrogenase (BDH). Biochemistry and Molecular Biology International 1995, 35:65-77.
82. Krueger R.G., Staneck L.D., Boehlecke J.M. Tumor-associated antigens in human myeloma. Journal of the National Cancer Institute 1976, 56:711-715.
83. Kersten S. Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Research 2008, 2008:132960.
84. Haluzik M.M., Lacinova Z., Dolinkova M., Haluzikova D., Housa D., Horinek A., et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 2006, 147:4517-4524.
85. Nagasawa T., Inada Y., Nakano S., Tamura T., Takahashi T., Maruyama K., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. European Journal of Pharmacology 2006, 536:182-191.
86. Chan S.M., Sun R.Q., Zeng X.Y., Choong Z.H., Wang H., Watt M.J., et al. Activation of PPARalpha ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased ER stress. Diabetes 2013, 62:2095-2105.
87. Hwang B., Wu P., Harris R.A. Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet. FEBS Journal 2012, 279:1883-1893.
88. Sasaki Y., Shimada T., Iizuka S., Suzuki W., Makihara H., Teraoka R., et al. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. European Journal of Pharmacology 2011, 662:1-8.
89. Tailleux A., Wouters K., Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochimica et Biophysica Acta 2012, 1821:809-818.
90. Thomassen M.S., Christiansen E.N., Norum K.R. Characterization of the stimulatory effect of high-fat diets on peroxisomal beta-oxidation in rat liver. Biochemical Journal 1982, 206:195-202.
91. Ye J.M., Doyle P.J., Iglesias M.A., Watson D.G., Cooney G.J., Kraegen E.W. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001, 50:411-417.
92. Fabbrini E., Mohammed B.S., Korenblat K.M., Magkos F., McCrea J., Patterson B.W., et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. Journal of Clinical Endocrinology and Metabolism 2010, 95:2727-2735.
93. Oosterveer M.H., Grefhorst A., van Dijk T.H., Havinga R., Staels B., Kuipers F., et al. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. Journal of Biological Chemistry 2009, 284:34036-34044.
94. Chen X., Matthews J., Zhou L., Pelton P., Liang Y., Xu J., et al. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist. Metabolism 2008, 57:1516-1525.
95. Guerre-Millo M., Gervois P., Raspe E., Madsen L., Poulain P., Derudas B., et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. Journal of Biological Chemistry 2000, 275:16638-16642.
96. Schafer H.L., Linz W., Falk E., Glien M., Glombik H., Korn M., et al. AVE8134, a novel potent PPARalpha agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats. Acta pharmacologica Sinica 2012, 33:82-90.
97. Enger S.C., Johnsen V., Samuelsen A., Laws E.A. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease. Acta Medica Scandinavica 1977, 201:563-566.
98. Ferrari C., Frezzati S., Romussi M., Bertazzoni A., Testori G.P., Antonini S., et al. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia. Metabolism 1977, 26:129-139.
99. Ferrari C., Testori G.P., Bertazzoni A., Romussi M., Caldara R., Frezzati S. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes. Hormone and Metabolic Research= Hormon- und Stoffwechselforschung= Hormones et metabolisme 1978, 10:4-6.
100. Kobayashi M., Shigeta Y., Hirata Y., Omori Y., Sakamoto N., Nambu S., et al. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care 1988, 11:495-499.
101. Anderlova K., Dolezalova R., Housova J., Bosanska L., Haluzikova D., Kremen J., et al. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiological Research 2007, 56:579-586.
102. Belfort R., Berria R., Cornell J., Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2010, 95:829-836.
103. Perreault L., Bergman B.C., Hunerdosse D.M., Howard D.J., Eckel R.H. Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. Metabolism 2011, 60:1107-1114.
104. Subramanian S., DeRosa M.A., Bernal-Mizrachi C., Laffely N., Cade W.T., Yarasheski K.E., et al. PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. American Journal of Physiology - Endocrinology and Metabolism 2006, 291:E1365-E1371.
105. Motojima K., Seto K. Fibrates and statins rapidly and synergistically induce pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice. Biological and Pharmaceutical Bulletin 2003, 26:954-958.
106. Walters M.W., Wallace K.B. Urea cycle gene expression is suppressed by PFOA treatment in rats. Toxicology Letters 2010, 197:46-50.
107. Edvardsson U., von Lowenhielm H.B., Panfilov O., Nystrom A.C., Nilsson F., Dahllof B. Hepatic protein expression of lean mice and obese diabetic mice treated with peroxisome proliferator-activated receptor activators. Proteomics 2003, 3:468-478.
108. Leonard J.F., Courcol M., Mariet C., Charbonnier A., Boitier E., Duchesne M., et al. Proteomic characterization of the effects of clofibrate on protein expression in rat liver. Proteomics 2006, 6:1915-1933.
109. Makino T., Kinoshita J., Arakawa S., Ito K., Ando Y., Yamoto T., et al. Comprehensive analysis of hepatic gene and protein expression profiles on phenobarbital- or clofibrate-induced hepatic hypertrophy in dogs. Journal of Toxicological Sciences 2009, 34:647-661.
110. Sheikh K., Camejo G., Lanne B., Halvarsson T., Landergren M.R., Oakes N.D. Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. American Journal of Physiology - Endocrinology and Metabolism 2007, 292:E1157-E1165.
111. Edgar A.D., Tomkiewicz C., Costet P., Legendre C., Aggerbeck M., Bouguet J., et al. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicology Letters 1998, 98:13-23.
112. Thulin P., Rafter I., Stockling K., Tomkiewicz C., Norjavaara E., Aggerbeck M., et al. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicology and Applied Pharmacology 2008, 231:1-9.
113. Tomkiewicz C., Muzeau F., Edgar A.D., Barouki R., Aggerbeck M. Opposite regulation of the rat and human cytosolic aspartate aminotransferase genes by fibrates. Biochemical Pharmacology 2004, 67:213-225.
114. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:2160-2164.
115. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:4318-4323.
116. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Molecular Endocrinology 1997, 11:779-791.
117. Lin Q., Ruuska S.E., Shaw N.S., Dong D., Noy N. Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry 1999, 38:185-190.
118. Murakami K., Ide T., Suzuki M., Mochizuki T., Kadowaki T. Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochemical and Biophysical Research Communications 1999, 260:609-613.
119. Sanderson L.M., de Groot P.J., Hooiveld G.J., Koppen A., Kalkhoven E., Muller M., et al. Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics. PLoS One 2008, 3:e1681.
120. Oswal D.P., Balanarasimha M., Loyer J.K., Bedi S., Soman F.L., Rider S.D., et al. Divergence between human and murine peroxisome proliferator-activated receptor alpha ligand specificities. Journal of Lipid Research 2013, 54:2354-2365.
121. Fang X., Hu S., Xu B., Snyder G.D., Harmon S., Yao J., et al. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. American Journal of Physiology - Heart and Circulatory Physiology 2006, 290:H55-H63.
122. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodriguez De Fonseca F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003, 425:90-93.
123. Muga S.J., Thuillier P., Pavone A., Rundhaug J.E., Boeglin W.E., Jisaka M., et al. 8S-lipoxygenase products activate peroxisome proliferator-activated receptor alpha and induce differentiation in murine keratinocytes. Cell Growth & Differentiation 2000, 11:447-454.
124. Zomer A.W., van Der Burg B., Jansen G.A., Wanders R.J., Poll-The B.T., van Der Saag P.T. Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha. Journal of Lipid Research 2000, 41:1801-1807.
125. Hostetler H.A., Petrescu A.D., Kier A.B., Schroeder F. Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands. Journal of Biological Chemistry 2005, 280:18667-18682.
126. Sun Y., Alexander S.P., Garle M.J., Gibson C.L., Hewitt K., Murphy S.P., et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. British Journal of Pharmacology 2007, 152:734-743.
127. JØrgensen C., Krogsdam A.M., Kratchmarova I., Willson T.M., Knudsen J., Mandrup S., et al. Opposing effects of fatty acids and acyl-CoA esters on conformation and cofactor recruitment of peroxisome proliferator-activated receptors. Annals of the New York Academy of Sciences 2002, 967:431-439.
128. Elholm M., Dam I., Jorgensen C., Krogsdam A.M., Holst D., Kratchmarova I., et al. Acyl-CoA esters antagonize the effects of ligands on peroxisome proliferator-activated receptor alpha conformation, DNA binding, and interaction with co-factors. Journal of Biological Chemistry 2001, 276:21410-21416.
129. Chakravarthy M.V., Lodhi I.J., Yin L., Malapaka R.R., Xu H.E., Turk J., et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 2009, 138:476-488.
130. Liu S., Brown J.D., Stanya K.J., Homan E., Leidl M., Inouye K., et al. Adiurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature 2013, 502:550-554.
131. Huang H., Starodub O., McIntosh A., Atshaves B.P., Woldegiorgis G., Kier A.B., et al. Liver fatty acid-binding protein colocalizes with peroxisome proliferator activated receptor alpha and enhances ligand distribution to nuclei of living cells. Biochemistry 2004, 43:2484-2500.
132. Huang H., Starodub O., McIntosh A., Kier A.B., Schroeder F. Liver fatty acid-binding protein targets fatty acids to the nucleus. Real time confocal and multiphoton fluorescence imaging in living cells. Journal of Biological Chemistry 2002, 277:29139-29151.
133. Hostetler H.A., McIntosh A.L., Atshaves B.P., Storey S.M., Payne H.R., Kier A.B., et al. L-FABP directly interacts with PPARalpha in cultured primary hepatocytes. Journal of Lipid Research 2009, 50:1663-1675.
134. McIntosh A.L., Atshaves B.P., Hostetler H.A., Huang H., Davis J., Lyuksyutova O.I., et al. Liver type fatty acid binding protein (L-FABP) gene ablation reduces nuclear ligand distribution and peroxisome proliferator-activated receptor-alpha activity in cultured primary hepatocytes. Archives of Biochemistry and Biophysics 2009, 485:160-173.
135. Wolfrum C., Borrmann C.M., Borchers T., Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:2323-2328.
136. Kozawa S., Honda A., Kajiwara N., Takemoto Y., Nagase T., Nikami H., et al. Induction of peroxisomal lipid metabolism in mice fed a high-fat diet. Molecular Medicine Reports 2011, 4:1157-1162.
137. Patsouris D., Reddy J.K., Muller M., Kersten S. Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 2006, 147:1508-1516.
138. Sunny N.E., Satapati S., Fu X., He T., Mehdibeigi R., Spring-Robinson C., et al. Progressive adaptation of hepatic ketogenesis in mice fed a high-fat diet. American Journal of Physiology - Endocrinology and Metabolism 2010, 298:E1226-1235.
139. Brady P.S., Marine K.A., Brady L.J., Ramsay R.R. Co-ordinate induction of hepatic mitochondrial and peroxisomal carnitine acyltransferase synthesis by diet and drugs. Biochemical Journal 1989, 260:93-100.
140. Ouali F., Djouadi F., Merlet-Benichou C., Riveau B., Bastin J. Regulation of fatty acid transport protein and mitochondrial and peroxisomal beta-oxidation gene expression by fatty acids in developing rats. Pediatric Research 2000, 48:691-696.
141. Duval C., Thissen U., Keshtkar S., Accart B., Stienstra R., Boekschoten M.V., et al. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes 2010, 59:3181-3191.
142. Gavrilova O., Haluzik M., Matsusue K., Cutson J.J., Johnson L., Dietz K.R., et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. Journal of Biological Chemistry 2003, 278:34268-34276.
143. Inoue M., Ohtake T., Motomura W., Takahashi N., Hosoki Y., Miyoshi S., et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochemical and Biophysical Research Communications 2005, 336:215-222.
144. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 2007, 5:426-437.
145. Garbow J.R., Doherty J.M., Schugar R.C., Travers S., Weber M.L., Wentz A.E., et al. Hepatic steatosis, inflammation, and ER stress in mice maintained long term on a very low-carbohydrate ketogenic diet. American Journal of Physiology - Gastrointestinal and Liver Physiology 2011, 300:G956-967.
146. Martin P.G., Guillou H., Lasserre F., Dejean S., Lan A., Pascussi J.M., et al. Novel aspects of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study. Hepatology 2007, 45:767-777.
147. Ren B., Thelen A.P., Peters J.M., Gonzalez F.J., Jump D.B. Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha. Journal of Biological Chemistry 1997, 272:26827-26832.
148. Lu Y., Boekschoten M.V., Wopereis S., Muller M., Kersten S. Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice. Physiological Genomics 2011, 43:1307-1318.
149. Nilsson A., Arey H., Pedersen J.I., Christiansen E.N. The effect of high-fat diets on microsomal lauric acid hydroxylation in rat liver. Biochimica et Biophysica Acta 1986, 879:209-214.
150. Yamazaki R.K., Shen T., Schade G.B. Adiet rich in (n-3) fatty acids increases peroxisomal beta-oxidation activity and lowers plasma triacylglycerols without inhibiting glutathione-dependent detoxication activities in the rat liver. Biochimica et Biophysica Acta 1987, 920:62-67.
151. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Molecular Cell 1999, 3:397-403.
152. Jia Y., Kim J.Y., Jun H.J., Kim S.J., Lee J.H., Hoang M.H., et al. Cyanidin is an agonistic ligand for peroxisome proliferator-activated receptor-alpha reducing hepatic lipid. Biochimica et Biophysica Acta 2013, 1831:698-708.
153. Jia Y., Kim J.Y., Jun H.J., Kim S.J., Lee J.H., Hoang M.H., et al. The natural carotenoid astaxanthin, a PPAR-alpha agonist and PPAR-gamma antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipid-loaded hepatocytes. Molecular Nutrition & Food Research 2012, 56:878-888.
154. Jia Y., Bhuiyan M.J., Jun H.J., Lee J.H., Hoang M.H., Lee H.J., et al. Ursolic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism. Bioorganic and Medicinal Chemistry Letters 2011, 21:5876-5880.
155. Rimando A.M., Nagmani R., Feller D.R., Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. Journal of Agricultural and Food Chemistry 2005, 53:3403-3407.
156. Shimura M., Hasumi A., Minato T., Hosono M., Miura Y., Mizutani S., et al. Isohumulones modulate blood lipid status through the activation of PPAR alpha. Biochimica et Biophysica Acta 2005, 1736:51-60.
157. Mezei O., Li Y., Mullen E., Ross-Viola J.S., Shay N.F. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and -independent mechanisms. Physiological Genomics 2006, 26:8-14.
158. Moya-Camarena S.Y., Vanden Heuvel J.P., Blanchard S.G., Leesnitzer L.A., Belury M.A. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha. Journal of Lipid Research 1999, 40:1426-1433.
159. Rakhshandehroo M., Hooiveld G., Muller M., Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 2009, 4:e6796.
160. Ducheix S., Podechard N., Lasserre F., Polizzi A., Pommier A., Murzilli S., et al. Asystems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARalpha. Biochimie 2013, 95:556-567.
161. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. Journal of Medicinal Chemistry 2000, 43:527-550.
162. Hoekstra M., Kruijt J.K., Van Eck M., Van Berkel T.J. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. Journal of Biological Chemistry 2003, 278:25448-25453.
163. Mandard S., Muller M., Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cellular and Molecular Life Sciences 2004, 61:393-416.
164. Rakhshandehroo M., Knoch B., Muller M., Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Research 2010, 2010.
165. Lee J.H., Giannikopoulos P., Duncan S.A., Wang J., Johansen C.T., Brown J.D., et al. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nature Medicine 2011, 17:812-815.
166. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabolism 2007, 5:415-425.
167. Lundasen T., Hunt M.C., Nilsson L.M., Sanyal S., Angelin B., Alexson S.E., et al. PPARalpha is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications 2007, 360:437-440.
168. Zandbergen F., Mandard S., Escher P., Tan N.S., Patsouris D., Jatkoe T., et al. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochemical Journal 2005, 392:313-324.
169. Kim H.B., Mendez R., Zheng Z., Chang L., Cai J., Zhang R., et al. Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor alpha to regulate metabolic hormone FGF21. Endocrinology 2014, 155:769-782.
170. Guillaumond F., Grechez-Cassiau A., Subramaniam M., Brangolo S., Peteri-Brunback B., Staels B., et al. Kruppel-like factor KLF10 is a link between the circadian clock and metabolism in liver. Molecular and Cellular Biology 2010, 30:3059-3070.
171. Zhang H., Chen Q., Yang M., Zhu B., Cui Y., Xue Y., et al. Mouse KLF11 regulates hepatic lipid metabolism. Journal of Hepatology 2012, 58:763-770.
172. Gill G., Ptashne M. Negative effect of the transcriptional activator GAL4. Nature 1988, 334:721-724.
173. McMullen P.D., Bhattacharya S., Woods C.G., Sun B., Yarborough K., Ross S.M., et al. Amap of the PPARalpha transcription regulatory network for primary human hepatocytes. Chemico-biological Interactions 2013, 209C:14-24.
174. van der Meer D.L., Degenhardt T., Vaisanen S., de Groot P.J., Heinaniemi M., de Vries S.C., et al. Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis. Nucleic Acids Research 2010, 38:2839-2850.
175. Boergesen M., Pedersen T.A., Gross B., van Heeringen S.J., Hagenbeek D., Bindesboll C., et al. Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor alpha in mouse liver reveals extensive sharing of binding sites. Molecular and Cellular Biology 2012, 32:852-867.
176. Motojima K., Passilly P., Peters J.M., Gonzalez F.J., Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. Journal of Biological Chemistry 1998, 273:16710-16714.
177. Guo L., Fang H., Collins J., Fan X.H., Dial S., Wong A., et al. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists. BMC Bioinformatics 2006, 7(Suppl.2):S18.
178. Krammer J., Digel M., Ehehalt F., Stremmel W., Fullekrug J., Ehehalt R. Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells. International Journal of Medical Sciences 2011, 8:599-614.
179. Aoyama T., Peters J.M., Iritani N., Nakajima T., Furihata K., Hashimoto T., et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). Journal of Biological Chemistry 1998, 273:5678-5684.
180. Hsu M.H., Savas U., Griffin K.J., Johnson E.F. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. Journal of Biological Chemistry 2001, 276:27950-27958.
181. Schoonjans K., Watanabe M., Suzuki H., Mahfoudi A., Krey G., Wahli W., et al. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. Journal of Biological Chemistry 1995, 270:19269-19276.
182. Dongol B., Shah Y., Kim I., Gonzalez F.J., Hunt M.C. The acyl-CoA thioesterase I is regulated by PPARalpha and HNF4alpha via a distal response element in the promoter. Journal of Lipid Research 2007, 48:1781-1791.
183. Brandes R., Kaikaus R.M., Lysenko N., Ockner R.K., Bass N.M. Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation. Biochimica et Biophysica Acta 1990, 1034:53-61.
184. Poirier H., Niot I., Monnot M.C., Braissant O., Meunier-Durmort C., Costet P., et al. Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochemical Journal 2001, 355:481-488.
185. Simon T.C., Roth K.A., Gordon J.I. Use of transgenic mice to map cis-acting elements in the liver fatty acid-binding protein gene (Fabpl) that regulate its cell lineage-specific, differentiation-dependent, and spatial patterns of expression in the gut epithelium and in the liver acinus. Journal of Biological Chemistry 1993, 268:18345-18358.
186. Storch J., McDermott L. Structural and functional analysis of fatty acid-binding proteins. Journal of Lipid Research 2009, (Suppl.50):S126-S131.
187. Fourcade S., Savary S., Albet S., Gauthe D., Gondcaille C., Pineau T., et al. Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha. European Journal of Biochemistry 2001, 268:3490-3500.
188. Rampler H., Weinhofer I., Netik A., Forss-Petter S., Brown P.J., Oplinger J.A., et al. Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy. Molecular Genetics and Metabolism 2003, 80:398-407.
189. Leclercq S., Skrzypski J., Courvoisier A., Gondcaille C., Bonnetain F., Andre A., et al. Effect of dietary polyunsaturated fatty acids on the expression of peroxisomal ABC transporters. Biochimie 2008, 90:1602-1607.
190. Hunt M.C., Solaas K., Kase B.F., Alexson S.E. Characterization of an acyl-coA thioesterase that functions as a major regulator of peroxisomal lipid metabolism. Journal of Biological Chemistry 2002, 277:1128-1138.
191. Bardot O., Aldridge T.C., Latruffe N., Green S. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochemical and Biophysical Research Communications 1993, 192:37-45.
192. Marcus S.L., Miyata K.S., Zhang B., Subramani S., Rachubinski R.A., Capone J.P. Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:5723-5727.
193. Nicolas-Frances V., Dasari V.K., Abruzzi E., Osumi T., Latruffe N. The peroxisome proliferator response element (PPRE) present at positions -681/-669 in the rat liver 3-ketoacyl-CoA thiolase B gene functionally interacts differently with PPARalpha and HNF-4. Biochemical and Biophysical Research Communications 2000, 269:347-351.
194. Shimizu M., Takeshita A., Tsukamoto T., Gonzalez F.J., Osumi T. Tissue-selective, bidirectional regulation of PEX11 alpha and perilipin genes through a common peroxisome proliferator response element. Molecular and Cellular Biology 2004, 24:1313-1323.
195. Brandt J.M., Djouadi F., Kelly D.P. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. Journal of Biological Chemistry 1998, 273:23786-23792.
196. Mascaro C., Acosta E., Ortiz J.A., Marrero P.F., Hegardt F.G., Haro D. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. Journal of Biological Chemistry 1998, 273:8560-8563.
197. van Vlies N., Ferdinandusse S., Turkenburg M., Wanders R.J., Vaz F.M. PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochimica et Biophysica Acta 2007, 1767:1134-1142.
198. Wen G., Ringseis R., Eder K. Mouse OCTN2 is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha) via a PPRE located in the first intron. Biochemical Pharmacology 2010, 79:768-776.
199. Gulick T., Cresci S., Caira T., Moore D.D., Kelly D.P. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:11012-11016.
200. Frerman F.E. Acyl-CoA dehydrogenases, electron transfer flavoprotein and electron transfer flavoprotein dehydrogenase. Biochemical Society Transactions 1988, 16:416-418.
201. Rodriguez J.C., Gil-Gomez G., Hegardt F.G., Haro D. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. Journal of Biological Chemistry 1994, 269:18767-18772.
202. Kroetz D.L., Yook P., Costet P., Bianchi P., Pineau T. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. Journal of Biological Chemistry 1998, 273:31581-31589.
203. Muerhoff A.S., Griffin K.J., Johnson E.F. The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. Journal of Biological Chemistry 1992, 267:19051-19053.
204. Wanders R.J., Komen J., Kemp S. Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. FEBS Journal 2011, 278:182-194.
205. Miller C.W., Ntambi J.M. Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:9443-9448.
206. Cherkaoui-Malki M., Meyer K., Cao W.Q., Latruffe N., Yeldandi A.V., Rao M.S., et al. Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis. Gene Expression 2001, 9:291-304.
207. Yu S., Cao W.Q., Kashireddy P., Meyer K., Jia Y., Hughes D.E., et al. Human peroxisome proliferator-activated receptor alpha (PPARalpha) supports the induction of peroxisome proliferation in PPARalpha-deficient mouse liver. Journal of Biological Chemistry 2001, 276:42485-42491.
208. Dalen K.T., Ulven S.M., Arntsen B.M., Solaas K., Nebb H.I. PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver. Journal of Lipid Research 2006, 47:931-943.
209. Targett-Adams P., McElwee M.J., Ehrenborg E., Gustafsson M.C., Palmer C.N., McLauchlan J. APPAR response element regulates transcription of the gene for human adipose differentiation-related protein. Biochimica et Biophysica Acta 2005, 1728:95-104.
210. Dalen K.T., Schoonjans K., Ulven S.M., Weedon-Fekjaer M.S., Bentzen T.G., Koutnikova H., et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes 2004, 53:1243-1252.
211. Dalen K.T., Dahl T., Holter E., Arntsen B., Londos C., Sztalryd C., et al. LSDP5 is a PAT protein specifically expressed in fatty acid oxidizing tissues. Biochimica et Biophysica Acta 2007, 1771:210-227.
212. Wolins N.E., Quaynor B.K., Skinner J.R., Tzekov A., Croce M.A., Gropler M.C., et al. OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes 2006, 55:3418-3428.
213. Kadereit B., Kumar P., Wang W.J., Miranda D., Snapp E.L., Severina N., et al. Evolutionarily conserved gene family important for fat storage. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:94-99.
214. Viswakarma N., Yu S., Naik S., Kashireddy P., Matsumoto K., Sarkar J., et al. Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor alpha-like effector A, in mouse liver by peroxisome proliferator-activated receptor alpha and gamma. Journal of Biological Chemistry 2007, 282:18613-18624.
215. Matsusue K., Kusakabe T., Noguchi T., Takiguchi S., Suzuki T., Yamano S., et al. Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metabolism 2008, 7:302-311.
216. Costet P., Legendre C., More J., Edgar A., Galtier P., Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. Journal of Biological Chemistry 1998, 273:29577-29585.
217. Stienstra R., Mandard S., Patsouris D., Maass C., Kersten S., Muller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 2007, 148:2753-2763.
218. Liu A., Krausz K.W., Fang Z.Z., Brocker C., Qu A., Gonzalez F.J. Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARalpha and its relevance to hepatotoxicity. Archives of Toxicology 2014, 88:983-996.
219. Yamazaki T., Wakabayashi M., Ikeda E., Tanaka S., Sakamoto T., Mitsumoto A., et al. Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats. Biological and Pharmaceutical Bulletin 2012, 35:1509-1515.
220. Kok T., Wolters H., Bloks V.W., Havinga R., Jansen P.L., Staels B., et al. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology 2003, 124:160-171.
221. Ghonem N.S., Ananthanarayanan M., Soroka C.J., Boyer J.L. Peroxisome proliferator-activated receptor alpha activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology 2013, 59:1030-1042.
222. Hunt M.C., Yang Y.Z., Eggertsen G., Carneheim C.M., Gafvels M., Einarsson C., et al. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. Journal of Biological Chemistry 2000, 275:28947-28953.
223. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 2001, 7:53-58.
224. Chinetti G., Gbaguidi F.G., Griglio S., Mallat Z., Antonucci M., Poulain P., et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101:2411-2417.
225. Lopez D., McLean M.P. Activation of the rat scavenger receptor class B type I gene by PPARalpha. Molecular and Cellular Endocrinology 2006, 251:67-77.
226. Mardones P., Pilon A., Bouly M., Duran D., Nishimoto T., Arai H., et al. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. Journal of Biological Chemistry 2003, 278:7884-7890.
227. Bertolotti M., Concari M., Loria P., Abate N., Pinetti A., Guicciardi M.E., et al. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans. Arteriosclerosis Thrombosis and Vascular Biology 1995, 15:1064-1069.
228. Post S.M., Duez H., Gervois P.P., Staels B., Kuipers F., Princen H.M. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arteriosclerosis Thrombosis and Vascular Biology 2001, 21:1840-1845.
229. Stahlberg D., Angelin B., Einarsson K. Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes. Journal of Lipid Research 1989, 30:953-958.
230. Stahlberg D., Reihner E., Rudling M., Berglund L., Einarsson K., Angelin B. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase. Hepatology 1995, 21:1025-1030.
231. Gbaguidi G.F., Agellon L.B. The inhibition of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver X receptor alpha and peroxisome proliferator-activated receptor alpha heterodimer. Nucleic Acids Research 2004, 32:1113-1121.
232. Marrapodi M., Chiang J.Y. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. Journal of Lipid Research 2000, 41:514-520.
233. Li F., Patterson A.D., Krausz K.W., Tanaka N., Gonzalez F.J. Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis. Journal of Lipid Research 2012, 53:1625-1635.
234. Li T., Chiang J.Y. Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Research 2009, 2009:501739.
235. Szatmari I., Pap A., Ruhl R., Ma J.X., Illarionov P.A., Besra G.S., et al. PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. Journal of Experimental Medicine 2006, 203:2351-2362.
236. Sun Y., Ng L., Lam W., Lo C.K., Chan P.T., Yuen Y.L., et al. Identification and characterization of a novel mouse peroxisome proliferator-activated receptor alpha-regulated and starvation-induced gene, Ppsig. International Journal of Biochemistry and Cell Biology 2008, 40:1775-1791.
237. Jitrapakdee S., Slawik M., Medina-Gomez G., Campbell M., Wallace J.C., Sethi J.K., et al. The peroxisome proliferator-activated receptor-gamma regulates murine pyruvate carboxylase gene expression invivo and invitro. Journal of Biological Chemistry 2005, 280:27466-27476.
238. White H.M., Koser S.L., Donkin S.S. Differential regulation of bovine pyruvate carboxylase promoters by fatty acids and peroxisome proliferator-activated receptor-alpha agonist. Journal of Dairy Science 2011, 94:3428-3436.
239. Wu P., Peters J.M., Harris R.A. Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochemical and Biophysical Research Communications 2001, 287:391-396.
240. Fisher F.M., Estall J.L., Adams A.C., Antonellis P.J., Bina H.A., Flier J.S., et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) invivo. Endocrinology 2011, 152:2996-3004.
241. Potthoff M.J., Inagaki T., Satapati S., Ding X., He T., Goetz R., et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:10853-10858.
242. Jonker J.W., Suh J.M., Atkins A.R., Ahmadian M., Li P., Whyte J., et al. APPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 2012, 485:391-394.
243. Kersten S., Mandard S., Tan N.S., Escher P., Metzger D., Chambon P., et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. Journal of Biological Chemistry 2000, 275:28488-28493.
244. Rakhshandehroo M., Stienstra R., de Wit N.J., Bragt M.C., Haluzik M., Mensink R.P., et al. Plasma mannose-binding lectin is stimulated by PPARalpha in humans. American Journal of Physiology - Endocrinology and Metabolism 2012, 302:E595-E602.
245. Mattijssen F., Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochimica et Biophysica Acta 2012, 1821:782-789.
246. Tachibana K., Takeuchi K., Inada H., Sugimoto K., Ishimoto K., Yamashita M., et al. Human mannose-binding lectin 2 is directly regulated by peroxisome proliferator-activated receptors via a peroxisome proliferator responsive element. Journal of Biochemistry 2013, 154:265-273.
247. Rommelaere S., Millet V., Gensollen T., Bourges C., Eeckhoute J., Hennuyer N., et al. PPARalpha regulates the production of serum vanin-1 by liver. FEBS Letters 2013, 587:3742-3748.
248. van Diepen, J.A., Jansen, P.A., Ballak, D.B., Hijmans, A., Hooiveld, G.J., Mensink, R.P., etal. PPAR-alpha dependent regulation of Vanin-1 mediates hepatic lipid metabolism. Journal of Hepatology. In press.
249. Blaauboer B.J., van Holsteijn C.W., Bleumink R., Mennes W.C., van Pelt F.N., Yap S.H., et al. The effect of beclobric acid and clofibric acid on peroxisomal beta-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochemical Pharmacology 1990, 40:521-528.
250. Cattley R.C., DeLuca J., Elcombe C., Fenner-Crisp P., Lake B.G., Marsman D.S., et al. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?. Regulatory Toxicology and Pharmacology: RTP 1998, 27:47-60.
251. Lambe K.G., Woodyatt N.J., Macdonald N., Chevalier S., Roberts R.A. Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicology Letters 1999, 110:119-127.
252. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.C., Staels B., et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. Journal of Clinical Investigation 1995, 96:741-750.
253. Prieur X., Coste H., Rodriguez J.C. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. Journal of Biological Chemistry 2003, 278:25468-25480.
254. Schultze A.E., Alborn W.E., Newton R.K., Konrad R.J. Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. Journal of Lipid Research 2005, 46:1591-1595.
255. Prieur X., Lesnik P., Moreau M., Rodriguez J.C., Doucet C., Chapman M.J., et al. Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice. Biochimica et Biophysica Acta 2009, 1791:764-771.